[en] Background/Objectives: BRCA1, BRCA2, ATM, and CHEK2 are known cancer predisposition genes (CPGs), but tumor risk in patients with simultaneous pathogenic variants (PVs) in CPGs remains largely unknown. In this study, we describe six patients from five families with multiple cancers who coinherited a combination of PVs in these genes. Methods: PVs were identified using NGS DNA sequencing and were confirmed by Sanger. Results: Families 1, 2, and 3 presented PVs in BRCA2 and ATM, family 4 in BRCA2 and BRCA1, and family 5 in BRCA2 and CHEK2. PVs were identified using NGS DNA sequencing and were confirmed by Sanger. The first family included patients with kidney, prostate, and breast cancer, in addition to pancreatic adenocarcinomas. In the second family, a female had breast cancer, while a male from the third family had prostate, gastric, and pancreatic cancer. The fourth family included a male with pancreatic cancer, and the fifth family a female with breast cancer. Conclusions: The early age of diagnosis and the development of multiple cancers in the reported patients indicate a very high risk of cancer in double-heterozygous patients associated with PVs in HR-related CPGs. Therefore, in families with patients who differ from other family members in terms of phenotype, age of diagnosis, or type of cancer, the cascade testing needs to include the study of other CPGs.
Espenschied C.R. LaDuca H. Li S. McFarland R. Gau C.-L. Hampel H. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome J. Clin. Oncol. 2017 35 2568 2575 10.1200/JCO.2016.71.9260 28514183
Esplin E.D. Nielsen S.M. Bristow S.L. Garber J.E. Hampel H. Rana H.Q. Samadder N.J. Shore N.D. Nussbaum R.L. Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer JCO Precis. Oncol. 2022 6 e2100516 10.1200/PO.21.00516 36108258
Yadav S. Couch F.J. Germline Genetic Testing for Breast Cancer Risk: The Past, Present, and Future Am. Soc. Clin. Oncol. Educ. Book. 2019 39 61 74 10.1200/EDBK_238987 31099663
Rahman N. Mainstreaming genetic testing of cancer predisposition genes Clin. Med. 2014 14 436 439 10.7861/clinmedicine.14-4-436 25099850
Whitaker K.D. Obeid E. Daly M.B. Hall M.J. Cascade Genetic Testing for Hereditary Cancer Risk: An Underutilized Tool for Cancer Prevention JCO Precis. Oncol. 2021 5 1387 1396 10.1200/PO.21.00163 34994636
Yap T.A. Ashok A. Stoll J. Mauer E. Nepomuceno V.M. Blackwell K.L. Garber J.E. Meric-Bernstam F. Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines JAMA Netw. Open 2022 5 e2213070 10.1001/jamanetworkopen.2022.13070
Kotsopoulos J. Hathaway C.A. Narod S.A. Teras L.R. Patel A.V. Hu C. Yadav S. Couch F.J. Tworoger S.S. Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts Cancer Epidemiol. Biomark. Prev. 2023 32 1402 1410 10.1158/1055-9965.EPI-23-0041 37493628
Vietri M.T. Caliendo G. D’Elia G. Resse M. Casamassimi A. Minucci P.B. Dello Ioio C. Cioffi M. Molinari A.M. Five Italian Families with Two Mutations in BRCA Genes Genes 2020 11 1451 10.3390/genes11121451 33287145
Huang W. Bian J. Qian X. Shao L. Li H. Zhang L. Wang L. Case Report: Coinheritance of Germline Mutations in APC and BRCA1 in Colorectal Cancer Front. Oncol. 2021 11 658389 10.3389/fonc.2021.658389
Andrés R. Menao S. Arruebo M. Quílez E. Cardiel M.J. Double heterozygous mutation in the BRCA1 and ATM genes involved in development of primary metachronous tumours: A case report Breast Cancer Res. Treat. 2019 177 767 770 10.1007/s10549-019-05343-4
Slaught C. Berry E.G. Bacik L. Skalet A.H. Anadiotis G. Tuohy T. Leachman S.A. Clinical challenges in interpreting multiple pathogenic mutations in single patients Hered. Cancer Clin. Pract. 2021 19 15 10.1186/s13053-021-00172-3 33541411
Lavie O. Narod S. Lejbkowicz F. Dishon S. Goldberg Y. Gemer O. Rennert G. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population Ann. Oncol. 2011 22 964 966 10.1093/annonc/mdq460 20924075
Sokolenko A.P. Bogdanova N. Kluzniak W. Preobrazhenskaya E.V. Kuligina E.S. Iyevleva A.G. Aleksakhina S.N. Mitiushkina N.V. Gorodnova T.V. Bessonov A.A. et al. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations Breast Cancer Res. Treat. 2014 145 553 562 10.1007/s10549-014-2971-1
Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance Carcinogenesis 2010 31 955 960 10.1093/carcin/bgq064 20351092
Cortesi L. Piombino C. Toss A. Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors? J. Pers. Med. 2021 11 245 10.3390/jpm11040245 33800556
Chatterjee N. Walker G.C. Mechanisms of DNA damage, repair and mutagenesis Environ. Mol. Mutagen. 2017 58 235 263 10.1002/em.22087 28485537
Khanna K.K. Cancer Risk and the ATM Gene: A Continuing Debate JNCI J. Natl. Cancer Inst. 2000 92 795 802 10.1093/jnci/92.10.795 10814674
Yamamoto H. Hirasawa A. Homologous Recombination Deficiencies and Hereditary Tumors Int. J. Mol. Sci. 2021 23 348 10.3390/ijms23010348 35008774
Jonathan L. Philipp H. Charlie G. Michael F. Ignace V. Gordon R. Clare S. Werner M. Ronnie S.-F. Tamar S. et al. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer N. Engl. J. Med. 2012 366 1382 1392 10.1056/NEJMoa1105535
Moiseyenko V.M. Chubenko V.A. Moiseyenko F.V. Zhabina A.S. Gorodnova T.V. Komarov Y.I. Bogdanov A.A. Sokolenko A.P. Imyanitov E.N. Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation Med. Oncol. 2014 31 199 10.1007/s12032-014-0199-x
Conroy M. Borad M.J. Bryce A.H. Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma Cureus 2017 9 e1517 10.7759/cureus.1517 28959512
Alsop K. Fereday S. Meldrum C. deFazio A. Emmanuel C. George J. Dobrovic A. Birrer M.J. Webb P.M. Stewart C. et al. BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group J. Clin. Oncol. 2012 30 2654 2663 10.1200/JCO.2011.39.8545 22711857
Cybulski C. Nazarali S. Narod S.A. Multiple primary cancers as a guide to heritability Int. J. Cancer 2014 135 1756 1763 10.1002/ijc.28988 24945890
Hall M.J. Bernhisel R. Hughes E. Larson K. Rosenthal E.T. Singh N.A. Lancaster J.M. Kurian A.W. Germline pathogenic variants in the Ataxia Telangiectasia Mutated (ATM) gene are associated with high and moderate risks for multiple cancers Cancer Prev. Res. 2021 14 433 440 10.1158/1940-6207.CAPR-20-0448
Harvengt J. Lumaka A. Fasquelle C. Caberg J.H. Mastouri M. Janssen A. Palmeira L. Bours V. HIDEA syndrome: A new case report highlighting similarities with ROHHAD syndrome Front. Genet. 2023 14 1137767 10.3389/fgene.2023.1137767
Richards S. Aziz N. Bale S. Bick D. Das S. Gastier-Foster J. Grody W.W. Hegde M. Lyon E. Spector E. et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology Genet. Med. 2015 17 405 424 10.1038/gim.2015.30
Desmet F.-O. Hamroun D. Lalande M. Collod-Béroud G. Claustres M. Béroud C. Human Splicing Finder: An online bioinformatics tool to predict splicing signals Nucleic Acids Res. 2009 37 e67 10.1093/nar/gkp215 19339519
Ware M.D. DeSilva D. Sinilnikova O.M. Stoppa-Lyonnet D. Tavtigian S.V. Mazoyer S. Does nonsense-mediated mRNA decay explain the ovarian cancer cluster region of the BRCA2 gene? Oncogene 2006 25 323 328 10.1038/sj.onc.1209033
Richardson M.E. Hu C. Lee K.Y. LaDuca H. Fulk K. Durda K.M. Deckman A.M. Goldgar D.E. Monteiro A.N.A. Gnanaolivu R. et al. Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance Am. J. Hum. Genet. 2021 108 458 468 10.1016/j.ajhg.2021.02.005
Guidugli L. Pankratz V.S. Singh N. Thompson J. Erding C.A. Engel C. Schmutzler R. Domchek S. Nathanson K. Radice P. et al. A classification model for BRCA2 DNA binding domain missense variants based on homology directed repair activity Cancer Res. 2013 73 265 275 10.1158/0008-5472.CAN-12-2081
Rebbeck T.R. Friebel T.M. Friedman E. Hamann U. Huo D. Kwong A. Olah E. Olopade O.I. Solano A.R. Teo S.-H. et al. Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations Hum. Mutat. 2018 39 593 620 10.1002/humu.23406 29446198
Laitman Y. Friebel T.M. Yannoukakos D. Fostira F. Konstantopoulou I. Figlioli G. Bonanni B. Manoukian S. Zuradelli M. Tondini C. et al. The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries Hum. Mutat. 2019 40 e1 e23 10.1002/humu.23842 31209999
Demir S. Tozkir H. Gurkan H. Atli E.I. Yalcintepe S. Atli E. Sezer A. Eker D. Tuncbilek N. Tastekin E. et al. Genetic screening results of individuals with high risk BRCA- related breast/ovarian cancer in Trakya region of Turkey J. BUON 2020 25 1337 1347 32862574
Mitui M. Nahas S. Du L. Yang Z. Lai C. Nakamura K. Arroyo S. Scott S. Purayidom A. Concannon P. et al. Functional and Computational Assessment of Missense Variants in the Ataxia-Telangiectasia Mutated (ATM) Gene: Mutations with Increased Cancer Risk Hum. Mutat. 2009 30 12 21 10.1002/humu.20805 18634022
Delia D. Mizutani S. Panigone S. Tagliabue E. Fontanella E. Asada M. Yamada T. Taya Y. Prudente S. Saviozzi S. et al. ATM protein and p53-serine 15 phosphorylation in ataxia-telangiectasia (AT) patients and at heterozygotes Br. J. Cancer 2000 82 1938 1945 10.1054/bjoc.2000.1168 10864201
Cavalieri S. Pozzi E. Gatti R.A. Brusco A. Deep-intronic ATM mutation detected by genomic resequencing and corrected in vitro by antisense morpholino oligonucleotide (AMO) Eur. J. Hum. Genet. 2013 21 774 778 10.1038/ejhg.2012.266 23211698
Borg Å. Haile R.W. Malone K.E. Capanu M. Diep A. Törngren T. Teraoka S. Begg C.B. Thomas D.C. Concannon P. et al. Characterization of BRCA1 and BRCA2 Deleterious Mutations and Variants of Unknown Clinical Significance in Unilateral and Bilateral Breast Cancer: The WECARE Study Hum. Mutat. 2010 31 E1200 E1240 10.1002/humu.21202 20104584
Li J. Williams B.L. Haire L.F. Goldberg M. Wilker E. Durocher D. Yaffe M.B. Jackson S.P. Smerdon S.J. Structural and Functional Versatility of the FHA Domain in DNA-Damage Signaling by the Tumor Suppressor Kinase Chk2 Mol. Cell 2002 9 1045 1054 10.1016/S1097-2765(02)00527-0 12049740
Boonen R.A.C.M. Wiegant W.W. Celosse N. Vroling B. Heijl S. Kote-Jarai Z. Mijuskovic M. Cristea S. Solleveld-Westerink N. van Wezel T. et al. Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk Cancer Res. 2022 82 615 631 10.1158/0008-5472.CAN-21-1845
Cybulski C. Wokołorczyk D. Jakubowska A. Huzarski T. Byrski T. Gronwald J. Masojć B. Dębniak T. Górski B. Blecharz P. et al. Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer J. Clin. Oncol. 2011 29 3747 3752 10.1200/JCO.2010.34.0778
Couch F.J. Shimelis H. Hu C. Hart S.N. Polley E.C. Na J. Hallberg E. Moore R. Thomas A. Lilyquist J. et al. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer JAMA Oncol. 2017 3 1190 1196 10.1001/jamaoncol.2017.0424 28418444
Kuchenbaecker K.B. Hopper J.L. Barnes D.R. Phillips K.-A. Mooij T.M. Roos-Blom M.-J. Jervis S. van Leeuwen F.E. Milne R.L. Andrieu N. et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers JAMA 2017 317 2402 2416 10.1001/jama.2017.7112 28632866
Graffeo R. Rana H.Q. Conforti F. Bonanni B. Cardoso M.J. Paluch-Shimon S. Pagani O. Goldhirsch A. Partridge A.H. Lambertini M. et al. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D Breast 2022 65 32 40 10.1016/j.breast.2022.06.003 35772246
Levy-Lahad E. Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers Br. J. Cancer 2007 96 11 15 10.1038/sj.bjc.6603535 17213823
Duzkale Teker N. Eyerci N. Double Heterozygous Mutations in the BRCA2 and ATM Genes: A Case Report and Review of the Literature Breast Care 2021 16 412 417 10.1159/000511430 34602949
Maxwell K.N. Domchek S.M. Nathanson K.L. Robson M.E. Population Frequency of Germline BRCA1/2 Mutations J. Clin. Oncol. 2016 34 4183 4185 10.1200/JCO.2016.67.0554 27551127
Swift M. Morrell D. Cromartie E. Chamberlin A.R. Skolnick M.H. Bishop D.T. The incidence and gene frequency of ataxia-telangiectasia in the United States Am. J. Hum. Genet. 1986 39 573 583
Nguyen-Dumont T. Dowty J.G. Steen J.A. Renault A.-L. Hammet F. Mahmoodi M. Theys D. Rewse A. Tsimiklis H. Winship I.M. et al. Population-Based Estimates of the Age-Specific Cumulative Risk of Breast Cancer for Pathogenic Variants in CHEK2: Findings from the Australian Breast Cancer Family Registry Cancers 2021 13 1378 10.3390/cancers13061378
Sukumar J. Kassem M. Agnese D. Pilarski R. Ramaswamy B. Sweet K. Sardesai S. Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: A case series Breast Cancer Res. Treat. 2021 186 569 575 10.1007/s10549-021-06095-w
Wang A. Everett J.N. Chun J. Cen C. Simeone D.M. Schnabel F. Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer Sci. Rep. 2021 11 12491 10.1038/s41598-021-91971-0
Hall M.J. McSweeny M.J. Rainey K. Campbell H. Nguyen C. Neumann C. Risks and implications of multiple actionable pathogenic germline variants discovered by panel-based cancer predisposition testing J. Clin. Oncol. 2023 41 792 10.1200/JCO.2023.41.4_suppl.792
Weitzel J.N. Blazer K.R. Nehoray B. Kidd J. Slavin T.P. Solomon I. Niell-Swiller M. Rybak C. Saam J. Assessment of the clinical presentation of patients with at least two deleterious mutations on multi-gene panel testing J. Clin. Oncol. 2015 33 1514 10.1200/jco.2015.33.15_suppl.1514
Dal Buono A. Poliani L. Greco L. Bianchi P. Barile M. Giatti V. Bonifacio C. Carrara S. Malesci A. Laghi L. Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients with Pancreatic Cancer or Suspected Related Hereditary Syndromes: Historical Prospective Analysis Cancers 2023 15 1852 10.3390/cancers15061852 36980738
